Bala Ambati

The world’s youngest medical school graduate (at the age of 17 years), and voted number 1 in our top 40 under 40 Power List, Ambati was first to describe the use of bevacizumab for corneal transplant rejection and has developed numerous surgical techniques. Ambati is Professor of Ophthalmology at the University of Utah and President of iVeena, an ocular drug delivery device company. His research interests include the treatments for corneal neovascularization and novel drug delivery methods.